Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 2,442.5% in July

Key Points

• Daiichi Sankyo Co., Ltd. experienced a substantial increase in short interest in July, rising by 2,442.5% from 4,000 to 101,700 shares.
• The company's stock price rose by 0.8%, reaching $24.54, with a market capitalization of $46.49 billion and a P/E ratio of 23.83.
• Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating, indicating positive sentiment towards the stock's future performance.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 101,700 shares, agrowthof2,442.5% from the July 15th total of 4,000 shares. Currently,0.0% of the shares of the stock are short sold. Based on an average daily volume of 460,100 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 460,100 shares, the short-interest ratio is presently 0.2 days. Currently,0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock has a consensus rating of "Strong Buy".

Daiichi Sankyo Stock Performance

DSNKY traded up $1.24 during trading on Tuesday, reaching $26.98. The company's stock had a trading volume of 200,037 shares, compared to its average volume of 217,483. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.85 and a current ratio of 2.53. Daiichi Sankyo has a 52-week low of $20.92 and a 52-week high of $42.48. The company has a market capitalization of $51.11 billion and a price-to-earnings ratio of 26.19. The company's fifty day moving average price is $23.81 and its 200-day moving average price is $24.15.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.